Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SALVAT, Kwang Dong sign Tarafenacin development agreement
As per the terms of the agreement, Kwang Dong will develop and commercialise Tarafenacin in South Korea. Additionally, the terms of the agreement include an upfront payment and
As per the terms of the agreement, Kwang Dong will develop and commercialise Tarafenacin in South Korea. Additionally, the terms of the agreement include an upfront payment and
Amylin and Lilly said that in the study, Byetta was associated with a lower incidence of CVD-related events than insulin, thiazolidinediones (TZDs) and sulfonylureas and a comparable incidence
Merck Research Laboratories clinical research director Elizabeth Garner said that they were pleased with the outcome of the meeting and look forward to continued discussions with the FDA
PerformRx will help the California Department of General Services provide efficient pharmacy benefit management services to portions of the state’s population covered by DGS’s statewide pharmaceutical program. As
The new fulfillment agreement is expected to improve the back orders for the remainder of 2010 and reduce the insufficient levels of stock needed to complete all orders.
The first of these products, Striant SR, marketed under license from Columbia Laboratories, is a prescription only medicine for testosterone replacement therapy in men suffering from hypogonadism. The
The funding has been awarded for four product programs, including the company’s differentiated anti-IL17 monoclonal antibody (mAb) program. AnaptysBio said that the QTDP grant awards will help fund
Assisted by its accounting firm Langdon & Co of Garner, the grant application submitted by Yukon resulted in this grant in furtherance of its ‘development of a safe,
Lilly said that Effient analysis involved 346 patients with acute coronary syndrome (ACS) who had received either study drug and subsequently underwent isolated CABG at some point during
The Phase II TOMORROW study was a 12-month, randomised, double-blind, placebo-controlled trial, aimed to evaluate the impact of oral BIBF1120 on decline in forced vital capacity (FVC) in